Cantor Fitzgerald Predicts BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Bicycle Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($4.24) per share for the year. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the prior year, the business earned ($1.26) earnings per share. The company’s revenue was down 50.0% on a year-over-year basis.

Several other brokerages also recently issued reports on BCYC. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. B. Riley lowered their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $33.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. Stephens restated an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.25.

Bicycle Therapeutics Trading Up 0.2 %

NASDAQ BCYC opened at $13.23 on Thursday. Bicycle Therapeutics has a 1 year low of $12.17 and a 1 year high of $28.67. The company has a fifty day simple moving average of $16.92 and a 200 day simple moving average of $21.34. The company has a market cap of $913.53 million, a P/E ratio of -4.02 and a beta of 0.92.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Assetmark Inc. bought a new position in Bicycle Therapeutics during the 3rd quarter valued at about $34,000. GAMMA Investing LLC raised its stake in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after acquiring an additional 1,038 shares during the last quarter. Avior Wealth Management LLC acquired a new position in shares of Bicycle Therapeutics in the 4th quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. grew its position in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, COO Alistair Milnes sold 4,578 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $64,504.02. Following the sale, the chief operating officer now directly owns 100,724 shares of the company’s stock, valued at approximately $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the sale, the chief accounting officer now owns 19,241 shares in the company, valued at approximately $483,141.51. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,933 shares of company stock valued at $549,501 in the last 90 days. 8.50% of the stock is currently owned by company insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.